Apimeds Pharmaceuticals US, Inc. (APUS) Form 10-Q — May 26, 2026
Apimeds Pharmaceuticals US, Inc. reported a net loss of $35.1 million for the three months ended March 31, 2026, driven primarily by a $22.1 million unrealized loss on its digital asset holdings (Bitcoin, Tether, and NILA tokens) acquired via the MindWave Innovations merger. The filing includes explicit going-concern language, citing substantial doubt about the company's ability to continue as a going concern due to its accumulated deficit of $45.5 million and reliance on restricted cash and volatile crypto assets for liquidity.
Key figures
- Total Debt
- 14703698
- Total Assets
- 141219157
- Cash Position
- 979534
- Restricted Cash
- 8000000
- Advisory Fee Value
- 8113318
- Debt Default Amount
- 10900000
- Forbearance Expiry
- 2026-06-30
- Shares Outstanding
- 15091177
- Digital Assets Value
- 127815173
- Advisory Shares Issued
- 2515194
- Advisory Shares Committed
- 4558044
Price after filing
Close on the filing date to close N calendar days later (from $1.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.